Eli Lilly and
Company has announced an ambitious goal to expand global access to healthcare
for 30 million people in resource-limited settings by 2030. The
cornerstone of this goal - known as Lilly 30x30 - is a new five-year, $90
million investment in the Lilly Global Health Partnership, which will improve
access to treatment for diabetes, cancer and tuberculosis (TB).
One half of the $90
million commitment will come from the Eli Lilly and Company Foundation, the
other from company funds.
Lilly chairman,
president and CEO John Lechleiter said: "Over the last two decades,
we have made tremendous progress in expanding access to quality care in poorer
communities, but we can and must do more. Lilly 30x30 is a company-wide mandate
to achieve a six-fold increase in the number of people we reach annually,
outside of our traditional business."
The Lilly Global
Health Partnership also includes a new $15 million commitment to the Infectious
Disease Research Institute (IDRI). This new commitment extends an eight-year
collaboration to accelerate early-stage drug discovery and preclinical
development for potential new TB medicines.
"We will engage
the entire Lilly organisation to ensure that our aspirational goals are
met," Lechleiter added. "The investments announced today
will help millions more [to] benefit from Lilly's life-saving work and
accelerate our contributions toward the U.N. Sustainable Development
Goals."
www.gmpviolations.com
(This story has not been edited by GMP Violations staff and is auto-generated
from a syndicated feed.)
Disclaimer: The Logos/Images posted here are belongs
to respective to Authority / owners of firm.
Posts
0 comments:
Post a Comment